Novartis Holds Out For Happier Second Half Of 2021
Sales Inch Up 1% But Cosentyx and Entresto Keep Climbing
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
But advisory committee members debate how to define the target population for a new indication, shying away from use of ‘preserved’ to characterize heart failure patients with ejection fraction levels below normal but greater than the definition of ‘reduced’ EF.
As well as highlighting Novartis's burgeoning pipeline, the Swiss major's CEO is confident that its biggest earners will continue to growth for the next five years at least.